Skip to content
OpenCapital
Get started

Zoetis ZTS Dermatology — Revenue

Other product segments

Horses
$5.8B+13.9%
Dogs and Cats
$1.35B+11.6%
Parasiticides
$586M+2.4%
Vaccines
$519M+18.2%
Cattle
$399M-0.5%
Anti-infectives
$241M+1.3%
Pain and sedation
$203M-1.9%
Other pharmaceutical
$158M0.0%
Swine
$128M-7.9%
Animal health diagnostics
$117M+12.5%
Poultry
$117M-7.9%
Other Non Pharmaceuticals
$66M-7.0%
Fish
$65M+4.8%
Contract manufacturing & human health
$23M-23.3%
Sheep and other
$17M+6.3%

Similar metrics at other companies

PBH
PBHDermatologicals — Total revenues
$30.49M+4.8%
Aclaris Therapeutics logo
ACRSDermatology Therapeutics — Revenue
$1.46M+44.5%
Castle Biosciences logo
CSTLDermatologic — NET REVENUES
$41.11M-34.7%
Cencora logo
CORAnimal Health — Revenue
$1.44B+5.3%
Elanco Animal Health Inc. logo
ELANPet Health — Revenue
$710M+11.8%
Phibro Animal Health logo
PAHCAnimal Health — Revenue
$291.23M+12.7%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's dermatology — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's dermatology — revenue?
Zoetis (ZTS) reported dermatology — revenue of $349M in Q1 2026.
How has Zoetis's dermatology — revenue changed year-over-year?
Zoetis's dermatology — revenue decreased by 7.9% year-over-year, from $379M to $349M.
What is the long-term trend for Zoetis's dermatology — revenue?
Over 4 years (2021 to 2025), Zoetis's dermatology — revenue has grown at a 10.2% compound annual growth rate (CAGR), from $1.18B to $1.74B.
What does dermatology — revenue mean?
This metric represents the total gross sales generated from the company's portfolio of animal dermatology products, including treatments for allergic dermatitis and related skin conditions. It serves as a key indicator of the company's market penetration and therapeutic leadership within the companion animal health sector. Growth in this segment reflects the successful adoption of specialized veterinary pharmaceuticals and the expansion of the addressable market for chronic pet care.